Literature DB >> 25424919

Correlates of human papillomavirus vaccine series completion among young adult female initiators.

Mahbubur Rahman1, Tabassum H Laz, Christine McGrath, Abbey B Berenson.   

Abstract

Incomplete human papillomavirus (HPV) vaccination is a public health concern. The objective of this study was to examine the correlates of vaccine series completion among 18-26 year old US women using the Behavioral Risk Factor Surveillance System (BRFSS) data. Using BRFSS data collected during 2008-2010, we conducted multivariable logistic regression analysis to examine the correlates of HPV vaccine completion among HPV vaccine initiators. Among 656 women (18-26 years old) who initiated the HPV vaccine, the overall weighted vaccine series completion rate was 60.7%. It was 32.9%, 65.3%, and 69.9% in 2008, 2009, and 2010, respectively. Black and Hispanic women were less likely to complete the series compared with white women. Higher income, having a college degree and completion of the study in a more recent year were associated with higher completion rates. Thus, the reasons for HPV series non-completion may be multifactorial. Interventions targeting 18-26 year old female vaccine initiators with low income and education, and minority backgrounds may improve HPV vaccine series completion.

Entities:  

Keywords:  Behavioral Risk Factor Surveillance System; Correlates; HPV Vaccine; Human papillomavirus; Vaccine completion; Vaccine initiation; Young adult females

Mesh:

Substances:

Year:  2014        PMID: 25424919      PMCID: PMC4896774          DOI: 10.4161/hv.29633

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  19 in total

1.  Geographic variation in human papillomavirus vaccination uptake among young adult women in the United States during 2008-2010.

Authors:  Mahbubur Rahman; Tabassum H Laz; Abbey B Berenson
Journal:  Vaccine       Date:  2013-09-23       Impact factor: 3.641

2.  Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.

Authors:  Susan Hariri; Elizabeth R Unger; Maya Sternberg; Eileen F Dunne; David Swan; Sonya Patel; Lauri E Markowitz
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

3.  Burden of cervical cancer in the United States, 1998-2003.

Authors:  Meg Watson; Mona Saraiya; Vicki Benard; Steven S Coughlin; Lisa Flowers; Vilma Cokkinides; Molly Schwenn; Youjie Huang; Anna Giuliano
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

4.  Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey.

Authors:  Rachel Caskey; Stacy Tessler Lindau; G Caleb Alexander
Journal:  J Adolesc Health       Date:  2009-06-24       Impact factor: 5.012

5.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

6.  Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007.

Authors:  Nidhi Jain; Gary L Euler; Abigail Shefer; Pengjun Lu; David Yankey; Lauri Markowitz
Journal:  Prev Med       Date:  2008-12-06       Impact factor: 4.018

Review 7.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.

Authors:  F Xavier Bosch; Ann N Burchell; Mark Schiffman; Anna R Giuliano; Silvia de Sanjose; Laia Bruni; Guillermo Tortolero-Luna; Susanne Kruger Kjaer; Nubia Muñoz
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

8.  Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010.

Authors:  Tabassum H Laz; Mahbubur Rahman; Abbey B Berenson
Journal:  Cancer       Date:  2012-11-26       Impact factor: 6.860

9.  Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Authors:  Simon R M Dobson; Shelly McNeil; Marc Dionne; Meena Dawar; Gina Ogilvie; Mel Krajden; Chantal Sauvageau; David W Scheifele; Tobias R Kollmann; Scott A Halperin; Joanne M Langley; Julie A Bettinger; Joel Singer; Deborah Money; Dianne Miller; Monika Naus; Fawziah Marra; Eric Young
Journal:  JAMA       Date:  2013-05-01       Impact factor: 56.272

10.  Factors associated with human papillomavirus vaccination among young adult women in the United States.

Authors:  Walter W Williams; Peng-Jun Lu; Mona Saraiya; David Yankey; Christina Dorell; Juan L Rodriguez; Deanna Kepka; Lauri E Markowitz
Journal:  Vaccine       Date:  2013-04-30       Impact factor: 3.641

View more
  4 in total

Review 1.  Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.

Authors:  Tommy R Buchanan; Whitney S Graybill; Jennifer Young Pierce
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  Predictors of Human Papillomavirus Vaccine Completion Among Female and Male Vaccine Initiators in Family Planning Centers.

Authors:  Hannah R Simons; Zoe D Unger; Priscilla M Lopez; Julia E Kohn
Journal:  Am J Public Health       Date:  2015-10-15       Impact factor: 9.308

3.  HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US.

Authors:  Guodong Liu; Lan Kong; Ping Du
Journal:  Papillomavirus Res       Date:  2016-12

4.  Human Papillomavirus Vaccination Status and Parental Endorsement Intentions among Undergraduate Student Nurses.

Authors:  Ashley Hollins; Diane Wardell; Maria E Fernandez; Christine Markham; Vincent Guilamo-Ramos; Diane Santa Maria
Journal:  Int J Environ Res Public Health       Date:  2021-03-20       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.